

Table S1. Outcomes of infants by level of exposure to antenatal corticosteroids (ANS)

	Complete ANS		Partial ANS		No ANS	Complete v Partial
	n/total n (%)	ARR (95% CI) ^a	n/total n (%)	ARR (95% CI)	n/total n (%)	ARR (95% CI)
Total study population	N=7136		N=2533		N=1307	
Death						
By 36 wk' postmenstrual age	1352/7119 (19.0)	0.62 (0.57-0.68) ^b	591/2527 (23.4)	0.75 (0.68 – 0.83) ^b	513/1305 (39.3)	0.82 (0.76-0.90) ^b
Before discharge	1529/7104 (21.5)	0.66 (0.61-0.72) ^b	654/2520 (26.0)	0.77 (0.70 – 0.85) ^b	540/1302 (41.5)	0.85 (0.78-0.92) ^b
Due to bronchopulmonary dysplasia	138/7098 (1.9)	1.88 (1.08-3.27) ^{b,c}	33/2518 (1.3)	1.12 (0.59-2.11) ^c	16/1299 (1.2)	1.52 (1.03-2.25) ^{b,c}
Due to respiratory distress syndrome	475/7098 (6.7)	0.66 (0.55-0.80) ^b	222/2518 (8.8)	0.81 (0.66 – 0.99) ^{b,c}	171/1299 (13.2)	0.80 (0.68-0.94) ^{b,c}
Bronchopulmonary dysplasia (physiologic definition) or death by 36 wk' postmenstrual age	4382/7034 (62.3)	0.92 (0.89-0.96) ^b	1614/2504 (64.5)	0.97 (0.92 – 1.01)	940/1300 (72.3)	0.97 (0.94-1.01)
Population of survivors	N=5575		N=1866		N=762	
Bronchopulmonary dysplasia, physiologic definition	2847/5485 (51.9)	0.95 (0.88-1.02)	953/1843 (51.7)	0.98 (0.90 – 1.06)	396/755 (52.5)	0.999 (0.95-1.05)
Bronchopulmonary dysplasia, by use of supplemental oxygen at 36 wk' postmenstrual age, clinical definition	2982/5545 (53.8)	0.94 (0.88-1.01)	1008/1853 (54.4)	0.98 (0.91 – 1.06)	415/759 (54.7)	0.98 (0.93-1.02)
Respiratory distress syndrome	5478/5575 (98.3)	0.99 (0.99-0.998) ^b	1853/1866 (99.3)	1.00 (0.99-1.01)	760/762 (99.7)	0.99 (0.98-0.99) ^b
Surfactant use	4651/5575 (83.4)	0.90 (0.87-0.92) ^b	1665/1866 (89.2)	0.97 (0.94 – 0.99) ^b	702/762 (92.1)	0.93 (0.92-0.95) ^b
Mechanical ventilation	4973/5571 (89.3)	0.94 (0.92-0.96) ^b	1737/1865 (93.4)	0.98 (0.96 – 1.00)	723/762 (94.9)	0.96 (0.94-0.97) ^b
Pneumothorax	256/5575 (4.6)	0.74 (0.53-1.04) ^c	98/1866 (5.3)	0.88 (0.60 – 1.27) ^c	45/762 (5.9)	0.84 (0.66-1.07) ^c
Pulmonary hemorrhage	203/5575 (3.6)	0.68 (0.49-0.94) ^{b,c}	101/1866 (5.4)	0.95 (0.67 – 1.36) ^c	47/762 (6.2)	0.73 (0.57-0.93) ^{b,c}
Treatment with post-natal steroids for bronchopulmonary dysplasia	893/5420 (16.5)	0.97 (0.80-1.17)	320/1813 (17.7)	1.05 (0.86 – 1.28)	112/733 (15.3)	0.88 (0.78-0.98) ^{b,c}
Early onset sepsis	99/5575 (1.8)	0.61 (0.36-1.04) ^c	35/1866 (1.9)	0.82 (0.46-1.45) ^c	17/762 (2.2)	0.73 (0.49-1.10) ^c
Necrotizing enterocolitis ≥ stage 2	472/5575 (8.5)	0.96 (0.75-1.24) ^c	193/1865 (10.3)	1.10 (0.84-1.44) ^c	71/762 (9.3)	0.86 (0.72-1.03) ^c
Intracranial hemorrhage/periventricular leukomalacia	664/5549 (12.0)	0.56 (0.48-0.66) ^{b,c}	360/1860 (19.4)	0.88 (0.74-1.04) ^c	167/761 (21.9)	0.63 (0.56-0.71) ^{b,c}
Patent ductus arteriosus treated with indomethacin/ibuprofen	1743/5570 (31.3)	0.90 (0.81-0.99) ^b	697/1865 (37.4)	1.04 (0.93 – 1.16)	293/761 (38.5)	0.90 (0.84-0.96) ^b
Retinopathy of prematurity ≥ stage 3 or treated with ablation/anti-VEGF drug	932/5483 (17.0)	0.71 (0.61-0.82) ^{b,c}	388/1827 (21.2)	0.87 (0.74 – 1.02) ^c	178/753 (23.6)	0.82 (0.74-0.91) ^{b,c}
Respiratory support at discharge, oxygen	1778/5365 (33.1)	1.17 (1.03-1.33) ^{b,c}	605/1818 (33.3)	1.20 (1.05 – 1.38) ^{b,c}	195/740 (26.4)	0.98 (0.90-1.06) ^c
Prolonged hospital stay ≥ 120 d, all causes	1526/5442 (28.0)	0.86 (0.77-0.95) ^{b,c}	554/1839 (30.1)	1.00 (0.88 – 1.13)	235/752 (31.3)	0.92 (0.85-0.99) ^b
Population of survivors eligible for follow-up	N=2981		N=1145		N=471	
Respiratory support at 18-22 mo corrected age, ventilation/CPAP	49/2682 (1.8)	0.94 (0.41-2.14) ^c	18/1045 (1.7)	1.11 (0.46-2.69) ^d	7/422 (1.7)	0.93 (0.51-1.69) ^c
Oxygen at 18-22 mo corrected age	141/2682 (5.3)	0.99 (0.62-1.57) ^c	60/1045 (5.7)	1.24 (0.77 – 2.00) ^c	20/422 (4.7)	0.80 (0.58-1.11) ^{c,e}

ANS, antenatal corticosteroid; ARR, adjusted relative risk; CI, confidence interval; CPAP, continuous positive airway pressure; VEGF, vascular endothelial growth factor.

^a ARR and 95% CI are estimated with no ANS (not exposed to ANS) group used as referent category except for complete vs partial column where adjusted odds ratios and 95% CI are expressed for complete course of ANS compared to partial course of ANS-models adjust for birthweight, sex, multiple births, small for gestational age, maternal variables (age, marital status, race, diabetes, rupture of membranes >24 h, antepartum hemorrhage, and mode of delivery), center, and epoch; ^b Significant with P value <.05; ^c Does not adjust for center-model did not converge with center included; ^d Model does not adjust for center or diabetes-model did not converge with either variable included; ^e Significant interaction from separate models that also included ANS-epoch.